GCM
IOVA icon

Graham Capital Management’s Iovance Biotherapeutics IOVA Stock Holding History

Graham Capital Management’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-255,405
Closed -$2.45M – 1170
2022
Q3 		$2.45M Sell
255,405
-713,101
-74% -$8.22M 0.1% 166
2022
Q2 		$10.7M Buy
968,506
+924,398
+2,096% +$12.1M 0.43% 33
2022
Q1 		$734K Buy
+44,108
New +$682K 0.03% 420

Other funds holding IOVA

State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Graham Capital Management's IOVA Position: Q4 2022 in Review

Graham Capital Management sold out of Iovance Biotherapeutics (IOVA) in Q4 2022, closing a stake of 255,405 shares — an estimated $2.45M sold.

Graham Capital Management first reported a position in IOVA in Q1 2022 and held it in 3 quarters. The position peaked at $10.7M in Q2 2022. 218 funds tracked by Wall St. Rank hold IOVA as of Q4 2022.

  • Graham Capital Management reported no remaining Iovance Biotherapeutics position as of Q4 2022 after selling out during the quarter.
  • Graham Capital Management sold 255,405 Iovance Biotherapeutics shares in Q4 2022, an estimated $2.45M.
  • Graham Capital Management first reported a position in Iovance Biotherapeutics in Q1 2022 and held it in 3 quarters.
  • Graham Capital Management's Iovance Biotherapeutics position peaked at $10.7M in Q2 2022.
  • 218 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q4 2022.

Based on Graham Capital Management's 13F filing for Q4 2022, filed 14 Feb 2023.